Brefeldin A

Catalog No.S7046

Brefeldin A  Chemical Structure

Molecular Weight(MW): 280.36

Brefeldin A is a lactone antibiotic and ATPase inhibitor for protein transport with IC50 of 0.2 μM in HCT 116 cells, induces cancer cell differentiation and apoptosis. It could also improve the HDR(homology-directed repair) efficiency and be an enhancer of CRISPR-mediated HDR.

Size Price Stock Quantity  
In DMSO USD 80 In stock
USD 70 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

1 Customer Review

  • Cells were treated with brefeldin A or manumycin A, and the resulting supernatant was collected after 48 h for exosomal preparation (lanes 1 and 2), or exosomes obtained from C81 cells were trypsin-treated or freeze/thawed (F/T) and then trypsin-treated (lanes 3 and 4). Lanes 5 and 6, input exosome controls from C81 or CEM cells, respectively. Resulting exosomes were assayed for the presence of Tax by Western blotting.

    J Biol Chem, 2014, 289(32):22284-305.. Brefeldin A purchased from Selleck.

Purity & Quality Control

Choose Selective ATPase Inhibitors

Biological Activity

Description Brefeldin A is a lactone antibiotic and ATPase inhibitor for protein transport with IC50 of 0.2 μM in HCT 116 cells, induces cancer cell differentiation and apoptosis. It could also improve the HDR(homology-directed repair) efficiency and be an enhancer of CRISPR-mediated HDR.
Targets
ATPase (HCT 116) [1]
0.2 μM
In vitro

Brefeldin A is a fungal metabolite and blocks the forward transport between the endoplasmic reticulum and Golgi apparatus, Brefeldin A causes an impaired distribution of the membrane proteins. When HCT 116 human colon cancer cell is treated with Brefeldin A, morphological changes indicating cell differentiation are observed. Brefeldin A exerts its cytotoxic effects mainly by inducing differentiation and apoptosis in tumor cells. [1] The treatment of the strips with 20 μg/mL Brefeldin A for 6 hours completely abolishes the relaxation induced by bradykinin in the presence of 10mM indomethacin and 30 μM L-NOARG. The treatment with 20 μg/mL Brefeldin A substantially abolishes the bradykinin-induced decreases in [Ca2+]i and tension in the range of concentrations between 1 nM and 1 mM. Brefeldin A has no effect on the [Ca2+]i elevation in endothelial cells induced by bradykinin or substance P. [2] Addition of the fungal metabolite Brefeldin A does not affect the spontaneous phospholipid-dependent GTPS binding to myr-rARF1 but totally abolishs the retinal isotonic extract (RIE)-catalyzed exchange, with half-maximal inhibition at 2 μM Brefeldin A. Brefeldin A prevents a wide variety of membrane traffic pathways. Brefeldin A inhibits an ADP-ribosylation factor-specific guanine nucleotide exchange activity present in Golgi membranes or in brain cytosol. The complete prevention by Brefeldin A strongly suggests that the retinal extract contains an ARF-specific guanine nucleotide exchange factor. Retinal isotonic extract (RIE)-catalyzed GTPS release from both ADP-ribosylation factors (ARFs) is only partly inhibited by Brefeldin A, even at 300 μM. [3] Brefeldin A induces fusion of the Golgi apparatus with the ER. Brefeldin A abolishes the inhibitory effect of the CERT inhibitor HPA-12. Brefeldin A treatment, which induces fusion of the Golgi apparatus and the ER, rescues the limonoid-induced prevention of sphingomyelin biosynthesis. BFA treatment of CHO cells causes a 2 to 3 fold increase in sphingomyelin synthesis. [4] Apart from B-CLL cells, Brefeldin A reportedly causes apoptosis in multiple myeloma (U266, NCI-H929), Jurkat, HeLa, leukaemia (HL60, K562, BJAB), colon (HT-29) and prostate, as well as adenoid cystic sarcoma cells. The administration of 25 ng/mL of Brefeldin A completely blocks growth of HF4.9 and HF28RA cells, whereas higher Brefeldin A doses (75 ng/mL) are required to achieve the same effect in HF1A3 cells. Cell proliferation is inhibited within 24 hours in a dose-dependent manner and, depending on the cell line, almost complete cessation of 3H-thymdine incorporation is observed at 50-75 ng/mL of Brefeldin A (26%, 76%, 87% inhibition at 50 ng/ml and 75%, 87%, 92% inhibition at 75 ng/mL for HF1A3, HF4.9 and HF28RA cells respectively. Brefeldin A-induced cell killing is in a dose-dependent manner using YO-PRO 1/PI assay. [5] Brefeldin A could improve the HDR(homology-directed repair) efficiency. It is an enhancer of CRISPR-mediated HDR[6].

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
PC12 MkTRSpVv[3Srb36gRZN{[Xl? M1XyUlIh|ryP MmDQNUBp NEXtVZhqdmirYnn0d{B1cGViTD3EU3BCKCh{MNMg{txOMS2rbnT1Z4VlKHS{YX7zbYVvfCCHUluxM|IheGixc4Doc5J6dGG2aX;uxsA> MXGyOlM3OzF7MR?=
C2C12 NUL0WmlvTnWwY4Tpc44hSXO|YYm= MmS3NeKh|rypL33s NGHxToQyyqCq MlmyZYJwdGm|aHXzJIN6fG:taX7lJJJmdGWjc3Wg[pJwdSCFMlOxNkBugW:2dXLldy=> MYeyOlI6OTJ5OR?=
MEFs WT MnvuSpVv[3Srb36gRZN{[Xl? M3SzRVXDqM7:TR?= M4DBblIxKG2rbh?= M3rkPYNifXOnczDy[ZNq\GWwdDDlcpp6dWW|IIP1Z4gh[XNiTlHHWE1ITlBuIITvJIRq\m[3c3WgZoFkcyC2bzD0bIUhTVJ? NEDGfVgzPjF7NkCyNy=>
MEFs VAMP7 KO NUXPc21YTnWwY4Tpc44hSXO|YYm= MkPOOeKh|ryP NWPMO203OjBibXnu MUXjZZV{\XNicnXzbYRmdnRiZX76fY1meyC|dXPoJIF{KE6DR2StS2ZRNCC2bzDkbYZnfXOnIHLhZ4shfG9idHjlJGVT NF3MWWwzPjF7NkCyNy=>
SMCs M{i4[WZ2dmO2aX;uJGF{e2G7 M3LDOFExyqEEtXevcYw> MojjNE0yOiCq NEO0cpdFVVOR MVHzbI94eyCjIITy[Y5lKHSxd3Hy[JMh[SCqaXfo[ZIh[2:wY3XueJJifGmxbjDv[kB1cGViRWKvV3IhdmW2d3;yb{BqdiC2aHWgdIVzcW63Y3zlZZIh[XKnYdMg NUn6R2ZWOjZzN{KwPFA>
SMCs NUf4WYtiTnWwY4Tpc44hSXO|YYm= NXPVZWEzOTEEoNM1[{9udA>? Mkn4NE0yOiCq MXrEUXNQ NH;QT|Fk[XW|ZYOgZUB1emGwc3nlcpQhS2F{K9MgdoVt\WG|ZTDmdo9uKHSqZTDFVk9UWsLi M4rqcVI3OTd{MEiw
HEMC-1 MVjGeY5kfGmxbjDBd5NigQ>? MXSwMlHDqML3Zz;tcC=> NE\PPGUzPMLiaB?= NF\Fendk[XW|ZYOgZUBpcWeqZYKgbY5pcWKrdH;yfUBm\m[nY4Sgc44h\XixY4n0c5NqeyC2aHHuJI5w[2:mYYrvcIU> MoH1NlU6PzJ5NUm=
HUVEC M{m0e2Z2dmO2aX;uJGF{e2G7 NFzKWJcyOMLizszN NH;aUoIyyqCq M2TmfmROW09? M{XGeIFjd2yrc3jld{BpgXCxeHnhMYlv\HWlZXSgdoVt\WG|ZTDv[kBCXFBiZoLvcUBieGmlYXygZY5lKGKjc3;sZZRmemGuIIP1doZi[2W| MWWyOVk2Pjl6OB?=
HUVEC Mom2SpVv[3Srb36gRZN{[Xl? M1TYXlExyqEQvF2= NVvNSlNbOcLiaB?= M1zQc2ROW09? MorQbY5kemWjc3XzxsB1cGViboXtZoVzKGGwZDDpcpRmdnOrdImgc4Yh\my3b4Lld4NmdnRiYYLlZZMh\XOyZXPpZYxtgSCrbjDw[ZJqdnWlbHXhdkB{eGGlZR?= MljpNlU6PTZ7OEi=
Caco-2 NIfie29HfW6ldHnvckBCe3OjeR?= NH7ETlIzNjVizszN MWezNEBucW5? MVfheJRmdnWjdHXzJJRp\SCWR1[t{tIyNW2nZHnheIVlKGmwY4LlZZNmKGmwIGPFVnQh\nWwY4Tpc44> NYe5VXNjOjV7NUS5N|E>
NRK M4jwWmZ2dmO2aX;uJGF{e2G7 MUSyNFDjiIWwZz;tcC=> NYm2fphoPOLChXi= M2PyOGROW09? Mn[1doV{[3WnczDtbZRwfGmlIIDyc4dz\XO|aX;u M4P3cVI2QTR6NUi2
HeLa MXrGeY5kfGmxbjDBd5NigQ>? M4\HU|IxOOLChX7nM41t MWezJIg> NEj0V2ZFVVOR MUPpcoR2[2W|IITo[UBienSrZnnjbYFtKGK{ZXHrMZVxKG:oIITo[UBId2ypaTDjc41xdGW6 M13iblI2QTR6NUi2
COS MVvGeY5kfGmxbjDBd5NigQ>? NF7YXJAyKM7:Zz;tcC=> NEjBbGk{KGh? MljaZ49ueGyndHXsfUBlcXOyZYLz[ZMhfGinIFHQMVEhe2mpbnHsxsA> NVLESGRbOjV7MUW5NFA>
DF1  MlPiSpVv[3Srb36gRZN{[Xl? M13xW|HDqM7:TdMg NEDuVW41QCCq NUH3[Zh2TE2VTx?= NX[3SmxD\Gm|cHXyd4V{yqC2aHWg[Zhw\2Wwb4XzJGNUT2GuTlHjWFIheHKxdHXpci=> MoCxNlU5ODdyNUS=
nHDFs  Mnz0SpVv[3Srb36gRZN{[Xl? NFi0VXYyyqEQvF5CpC=> NWXBcXpCOsLiaB?= NUDYZnZteHKndnXueJMhfGinIHHzd4Vu[my7IH;mJIN6fG:|b3zpZ{Bkd2G2IIDyc5RmcW6|IH;ueI8hT2:uZ3mgcYVu[nKjbnXz M4HlUFI2Pzd{NkG2
FRT  Mm\nSpVv[3Srb36gRZN{[Xl? M2f4VVUh|rypL33s NEfNOlQzyqCq M4jK[IJtd2OtczD0doFn\mmla3nu[{B1cHKxdXfoJJRp\SCJb3znbUBkd22ybHX4JIJ6KGmwaHnibZRqdmdiRWKteI8uT2:uZ3mgeJJidnOyb4L0 Mkn5NlU4PjdzMUW=
FRT  M33nUGZ2dmO2aX;uJGF{e2G7 MV[1JO69\y:vbB?= NGPRSG0zyqCq NIf4cWFxemW4ZX70d{B1cGViaX7jdoVie2ViaX6gZ4xm[X[nZDFOtUB{fWK3bnn0d{B4cGWwIGvOZUteccLid3HzJJJm\HWlZXS= NGW0UnozPTd4N{GxOS=>
HepG2  MW\GeY5kfGmxbjDBd5NigQ>? NHS1b2sy6oDLwsXNxsA> MXOyOEBp M4TsV2ROW09? MkD6[IVkemWjc3XzJJRp\SCuZY\lcEBw\iCSWGKgcXJPSQ>? NUXpVWdwOjV4MU[1PVc>
SMCs MYnGeY5kfGmxbjDBd5NigQ>? MmO2Ne69\y:vTB?= MmHoN{Bp M4H6bIFk[3WvdXzheIV{KEOQUGmyJJBzd3SnaX6gbY4hfGinIFXSJINwdXCjcoTt[Y51KGGwZDDuc{Btd26pZYKgZ48udG:lYXzpfoVlKHerdHigeIhmKEexbHfpJI1iemunctMg M{XqWFI2PTh7NEK1
OB-6 NYLWNGlnSXCxcITvd4l{KEG|c3H5 NYHIdY1pOi55wrFOwG0> NH\YbW81QCCq NFzlWYdqdmS3Y3XzJIFxd3C2b4Ppdy=> NFvxTnAzPTV|MkS4NC=>
iPSC-CMs  MVfGeY5kfGmxbjDBd5NigQ>? Mnz3OVAxKG6pL33s NE[1[4s1QCCq NEjxbZpqdmO{ZXHz[ZMhfGinIHnueIVve2m2eTDv[kB1cGViaHnnbIVzKG2xYnnsbZR6KEyDTWDzJIF1KHSqZTDjc5N1KG:oIITo[UBtd3encjDtc4JqdGm2eTDzdIVkcWW| MnTINlU1QDh4Nk[=
SP-Nluc M4W2eGZ2dmO2aX;uJGF{e2G7 NWnVUFF{PSCvZz;tUC=> MkjXOkBp MWTEUXNQyqB? Mn3VZ4F2e2W|IHHuJIlv[3KnYYPlJIlvKHKncH;yeIVzKGGldHn2bZR6KGmwIITo[UBx[XKjc3n0[S=> NFzHb|EzPTN7Mkm5PC=>
PEXEL-Nluc MXfGeY5kfGmxbjDBd5NigQ>? NGTjZpg2KG2pL33M NEPXcnA3KGh? M4LsXGROW00EoB?= MmCxZ4F2e2W|IHHuJIlv[3KnYYPlJIlvKHKncH;yeIVzKGGldHn2bZR6KGmwIITo[UBx[XKjc3n0[S=> NWSzPWwzOjV|OUK5PVg>
H1299 M3vnWmZ2dmO2aX;uJGF{e2G7 MkfrNVAh|rypL33s M{D4b|I1KGh? M1LCbolv\HWlZYOgZZV1d3CqYXf5xsA> NGO2WpozPTN6OEm3NC=>
MDA-MB-231 NEC0Sm9E\WyuIG\pZYJqdGm2eTDBd5NigQ>? Mo\4NQKBmzVyIN88[{9uVA>? NI\YZW41QCCq MYnFR|UxyqB;IECuNFE3KML3Zz;tUC=> NYfHRYl2OjV|NU[1Olc>
MDA-MB-231 NIO4R3hCeG:ydH;zbZMhSXO|YYm= NFXqZZMxNjFizsznM41N M2TSN|QhcA>? NHL0VGpqdmS3Y3XzJIFxd3C2b4Ppdy=> MmLsNlU{PTZ3Nke=
MDA-MB-231 NXXmSmh3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjiOWQxNjBzL{CuNFUh|rypL33M M{jaOlI1KGh? MUDpcoNz\WG|ZYOgeIhmKG[{YXP0bY9vKG:oIIP1Zk1IOSClZXzsJIRm[nKrcx?= M4jX[FI2OzV4NU[3
MDA-MB-231 NV7aNohTSXCxcITvd4l{KEG|c3H5 NVjWOVliOC5yNfMAl|Eh|rypL33M NYrxZZJ5OjRiaB?= MYPpcoR2[2W|IGDBVnAhMHCxbImgRWRRNXKrYn;z[UBxd2y7bXXyZZNmNTFrIHPs[YF3[Wen MW[yOVM2PjV4Nx?=
MDA-MB-231 M3TwU2Z2dmO2aX;uJGF{e2G7 NGGycnox6oDVNUCg{txoN22O MnzkNlQhcA>? MVXpcohq[mm2czD0bIUh\m:{bXH0bY9vKG:oIEPEJIFv\CB{RDDjc4xwdmmncx?= Mlq5NlU{PTZ3Nke=
A172 NXrSPFhvTnWwY4Tpc44hSXO|YYm= MV6xNOKh|rypL33s NUXKXZB1PMLiaB?= NUGzbJRlTE2VT9Mg MXfy[ZN2dHS|IHnuJJRp\SC{ZYTyc4dz[WSnIITyZY5{eG:{dDDv[kBndHWxcnXzZ4VvfCCpcnHueYxmew>? MoHJNlUzOzl3MEe=
KMS-6 NXrTO3FTTnWwY4Tpc44hSXO|YYm= M2jqc|HDqM7:TdMg MlPiNlQhcA>? MVjlfIhq[mm2czDoZYxnKHSqZTDz[YNz\XSrb36gc4Yh\2GuYX7pck1NUSCjczDkbYQhfGinIHPvcpRzd2x? NYrTOphDOjV{MkmxNlY>
MEC NVju[lNwTnWwY4Tpc44hSXO|YYm= NX23e3ltOSEQvF2= NITvXGcyNjViaB?= M2DPbYNifXOnczDhJIRz[W2jdHnjJIRm[3KnYYPlJIlvKHSqZTDzeZJn[WOnIG\FS2ZTOg>? M3jyPVI2OjJ6OEG1
HEK293/hERG NUfl[FJOTnWwY4Tpc44hSXO|YYm= MVmxNOKh|ryP NYHB[WFZOcLiaB?= NEjKblVz\XO3bITzJIlvKGFidHnt[U1l\XCnbnTlcpQhemWmdXP0bY9vKG2jdIXy[UBpTVKJIIDyc5RmcW8EoB?= MmK1NlUzOTh2Nkm=
RBE4 M2\XU2Fxd3C2b4Ppd{BCe3OjeR?= MXGyxsDPxE1? M12x[lPjiJN{NNMgbC=> NXjCWolLcW6mdXPld{BieG:ydH;zbZMhfGmvZTDk[ZBmdmSnboTsfS=> NVrJZldEOjVzMkiwNlU>
RBE4 NIe4dXdHfW6ldHnvckBCe3OjeR?= NUfmbmdGOsLizszN M{SxW|PjiJN{NNMgbC=> NVHYcGdbcW6lcnXhd4V{KHSqZTDYRnAyKHC{b4TlbY4hdGW4ZXzzJIFnfGW{IEOgZY5lKDcEoHigc4YhfHKnYYTt[Y51 NFL6fpYzPTF{OECyOS=>
RBE4 MYTGeY5kfGmxbjDBd5NigQ>? MmXTNuKh|ryP NG[xTmk{6oDVMkVCpIg> M4DVN4lv[3KnYYPld{Bi[3SrdnWgZ4F{eGG|ZT2xNkBqdiCjIITpcYUu\GWyZX7k[Y51KG2jbn7lduKh M4LU[|I2OTJ6MEK1
RBE4 MVfGeY5kfGmxbjDBd5NigQ>? NILXPIszyqEQvF2= MnHjN-KBmzJ2wrDo NETW[YpqdmO{ZXHz[ZMhfGinIHzleoVteyCxZjDSU3MhfGmvZT3k[ZBmdmSnboTsfS=> M4DVZVI2OTJ6MEK1
RBE4 M3rud2Z2dmO2aX;uJGF{e2G7 NVLGXYs4OsLizszN MVKz5qCUOjUEoHi= NYXlWWl3cW6mdXPld{BiKGSnbHH5[YQh\GWybHX0bY9vKG:oIITo[UBGWiCFYUKrxsBkd262ZX70JIF1KDcEoHigc4YhcW6ldXLheIlwdiC|aXfubYZq[2GwdHz5 M2jYOFI2OTJ6MEK1
RBE4 M3XhSGZ2dmO2aX;uJGF{e2G7 NXyxNmlsOsLizszN NFOweVM{6oDVMkVCpIg> MWfpcoR2[2W|IHHuJI93\XKub3HkJI9nKEOjMjxCpIlvKHSqZTDtbZRw[2ixbnTybYEhcW5idHjlJIZqenO2IEdCpIghd2ZiaX7jeYJifGmxbjCodQKBkT{kgJmwMlAxOSliYoX0JGNiOiwEoHzleoVteyCrbjD0bIl{KG:{Z3Hu[Yxt\SCmZXPy[YF{\WRiYX\0[ZIhOTMEoHigc4YhcW6ldXLheIlwdg>? NXf5flA5OjVzMkiwNlU>
Huh-7  MmruSpVv[3Srb36gRZN{[Xl? MVKx{txoN22O M4jzW|PjiJN{NNMgbC=> MmnGbY5kemWjc3XzJJRp\SCuZY\lcEBw\iCDUFWxJIlvKGFidHnt[U1l\XCnbnTlcpQhdWGwbnXy NVnTZ4ppOjVyMk[xO|Q>
HepG2  NEizU4xHfW6ldHnvckBCe3OjeR?= NF3NS5Yy|rypL33M MYez5qCUOjUEoHi= MXXpcoNz\WG|ZYOgeIhmKGyndnXsJI9nKEGSRUGgbY4h[SC2aX3lMYRmeGWwZHXueEBu[W6wZYK= NIq4UVQzPTB{NkG3OC=>
H838-LKB1 NIXrV3FHfW6ldHnvckBCe3OjeR?= MWezNOKhdmdxbXy= NVHQVoJwOTJxMUigbC=> NYTybJROcW6lcnXhd4V{KHSqZTDwdo91\WmwIHzleoVteyCxZjDCbXDDqA>? NUXVW2I1OjVyMUGwPFI>
H838-KDLKB1  NULodmplTnWwY4Tpc44hSXO|YYm= NHLzOYk{OMLibnevcYw> M2PHUlEzNzF6IHi= NXvVXGJOcW6lcnXhd4V{KHSqZTDwdo91\WmwIHzleoVteyCxZjDCbXDDqA>? NX:4NY5HOjVyMUGwPFI>
H838-KDLKB1  M1vhT2Z2dmO2aX;uJGF{e2G7 M1f5OFMxyqCwZz;tcC=> NXTUOYdTOTJxMUigbC=> M2qybYlv[3KnYYPld{B1cGVibHX2[Yx{KG:oIIDoc5NxcG:{eXzheIVlKGWLRkNOtUApeGixc4Doc{1mUUZ{zsGp Ml;WNlUxOTFyOEK=
3T3-L1 NVHqWWtpTnWwY4Tpc44hSXO|YYm= M1izbVUh|rypL33s MX[zNEBucW5? NVrBWmE5dWmvaXPzJJRp\SCnZn\lZ5R{KG:oIHnud5VtcW5iYX7kJINifXOnczDyc4J2e3RicHjvd5Bpd3K7bHH0bY9vKG:oIFHreEApW2W{IES3N{kh[W6mIIDoc5NxcG:{eXzheIlwdiCxZjDBV|E3OCBqVHjyJFY1OiCjbnSgV4VzKDV6ODm= M4XaW|I1QDR|OEK3
3T3-L1 NXvqTWZoTnWwY4Tpc44hSXO|YYm= MYC1JO69\y:vbB?= NIL6S2I{OCCvaX6= MUDy[YNieGm2dXzheIV{KGmwc4XsbY4h[WO2aX;uJJdqfGhicnXzdIVkfCC2bzDy[Yd2dGG2aX7nJGFsfCCjY4Tpeol1gSCjbnSgRXMyPjBicHjvd5Bpd3K7bHH0bY9v M33NblI1QDR|OEK3
3T3-L1 M4W3OGZ2dmO2aX;uJGF{e2G7 Mn7vOUDPxGdxbXy= MkDVN|AhdWmw M3PTe4NifXOnczDy[ZZmenOrYnzlJJJm\Gm|dILpZpV1cW:wIH;mJGdNXVR2 MkT3NlQ5PDN6Mke=
3T3-L1 NFXJbHdHfW6ldHnvckBCe3OjeR?= MYO1JO69\y:vbB?= NHTS[|MyyqCq M4TpTINifXOnczDy[YRqe3S{aXL1eIlwdiCxZjDHUHVVPCCkdYSgco91KGmwY4LlZZNmKGmwIHfseYNwe2VidYD0ZYtm MY[yOFg1Ozh{Nx?=
3T3-L1 NWSweZdJTnWwY4Tpc44hSXO|YYm= M1riO|Uh|rypL33s M4KxfVHDqGh? MYjjZZV{\XNicHjvd5Bpd3K7bHH0bY9vKG:oIITo[UBHd3iRMTD0doFve2O{aYD0bY9vKG[jY4Tvdi=> NWO1WmpROjR6NEO4Nlc>
HeLa  NY[yeodyTnWwY4Tpc44hSXO|YYm= NFHIUVU2KM7:Zz;tcC=> NHvxT4k{KGh? M3G1TINifXOnczDueYNt\WG{IHX4Z4x2e2mxbjDv[kB1cGViRn;4U|EhfHKjboPjdolxfGmxbjDmZYN1d3JiYX7kJIRm[3KnYYPld{B1emGwc3PybZB1cW:wIH;mJGZwgE9zLYLl[5Vt[XSnZDDn[Y5mew>? M3rYOVI1QDR|OEK3
HEK293 MWHGeY5kfGmxbjDBd5NigQ>? NIfITFg2yqEQvHevcYw> M2HtZ|EzyqCq M4C5eoFjd2yrc3jld{BEVUFvaX7keYNm\CCFUlXMSFIhe2WlcnX0bY9v MXuyOFY5PzR|MR?=
COS-1 MVHGeY5kfGmxbjDBd5NigQ>? MYS1JOK2\y:vbB?= NXSzVnhQOjRiaNMg NVT3XlRkemW|dILpZ5R{KGyxY3HsbZpifGmxbjDv[kBPSiCrbjD0bIUheGW{aX71Z4xm[XJicnXnbY9vyqB? M171d|I1PjdzN{Wx
PRP Mo\oSpVv[3Srb36gRZN{[Xl? MliyNVAh|ryP NGL2bmVi[nKxZ3H0[ZMhW0SILUJOtU1u\WSrYYTl[EBEYEOUNzDlfJRmem6jbHn6ZZRqd28EoB?= Mni2NlQ3Pjh5NUC=
RAW264.7 M{izeGFxd3C2b4Ppd{BCe3OjeR?= MoPQOEDPxE1? Mo\EOFghcA>? M4XrT4F1fGWwdXH0[ZMhfGinIHnubIljcXSrb36gc4Yhd3hvTFTMMYlv\HWlZXSgZZBweHSxc3nzJIFv\CC2aHWg[oFkcWyrdHH0bY9vKG:oIHPoc4xme3Sncn;sJIVn\my3eDDifUBC[y2qRT2xPGEuVkh{ MXqyOFY{QTB|Mh?=
MDMs M{i0VGFxd3C2b4Ppd{BCe3OjeR?= NIP4Z40yOOLCid88[{9udA>? M1m0WVEzNzF3IHi= NHnSS4NqdmS3Y3XzJIFxd3C2b4Ppdy=> NWHLN4xKOjR3NU[2PVU>
PMHs  MULGeY5kfGmxbjDBd5NigQ>? MUGxNQKBmzJy4pEJ{txoN22u MkjsNlTjiImq Ml36SG1UVw>? NVi2dVRicW6mdXPl[EBGWiC|dILld5M> M2rud|I1PDB5MkSy
PMHs  MnTkRZBweHSxc3nzJGF{e2G7 NFn5UGsyOOLCk{Kw5qCK|rypL33s NVnPVGlROjUkgJno NFzGWo5FVVOR NVjuc4RFcW6lcnXhd4V{KGOnbHyg[IVifGh? Mn65NlQ1ODd{NEK=
HEK293/tau M1jLcGZ2dmO2aX;uJGF{e2G7 NIC4bFc2KM7:TR?= M{jzRlEwOi92IHi= MmfrbY5lfWOnczDHc4xocSCocnHncYVvfGG2aX;uxsA> MYiyOFM3QDB6OR?=
HEK293/tau Mn\USpVv[3Srb36gRZN{[Xl? M2Dsb|Uh|ryP NXzqW|hbOyCq NWfXTJFNcW6mdXPld{B1[XViaInw[ZJxcG:|cHjvdplt[XSrb36= M3flOVI1OzZ6MEi5
ADF MVzGeY5kfGmxbjDBd5NigQ>? MX[xNEDPxE1? MkjaNVYhcA>? M2DpNYlvcGmkaYTzJJRp\SCcblPsNk1qdmS3Y3XkJJRz[W6|bH;jZZRqd25ib3[gR3JV MX[yOFIzQDJ|Mh?=
U373  NYjYfGdYTnWwY4Tpc44hSXO|YYm= M4nTWlExKM7:TR?= MVKxOkBp MXXpcohq[mm2czD0bIUhYm6FbEKtbY5lfWOnZDD0doFve2yxY3H0bY9vKG:oIFPSWC=> MljoNlQzOjh{M{K=
RKO-HIPK2i NEfDTlBHfW6ldHnvckBCe3OjeR?= NG\WZpkyOCEQvF2= M4nuRVE3KGh? NH\5eWxqdmirYnn0d{B1cGViWn7DcFIucW6mdXPl[EB1emGwc3zvZ4F1cW:wIH;mJGNTXA>? NWWwSnpPOjR{MkiyN|I>
ADF  NFzpZolHfW6ldHnvckBCe3OjeR?= MkD5NVAh|ryPwrC= M2j5UVYhcA>? NWfXcnRmcW2yYXnyd{B1cGViRFOgZYN1cX[jdHnvci=> MmPvNlQzOjh{M{K=
Huh7 M2DuWWZ2dmO2aX;uJGF{e2G7 NXO3OFczPSEQvHevcYw> MWO0JIg> NF3Ke2di[m:uaYPo[ZMhfGinIIPlZ5JmfGmxbjDv[kAhcW62cnHj[YxtfWyjcjDBdI9D MYmyOFExODF2MB?=
Huh7 MnzESpVv[3Srb36gRZN{[Xl? NGTDUJI2KM7:Zz;tcC=> MXqxJIg> NFPFW4Jk[XW|ZYOgZUB{cWewaX\pZ4FvfCCrbnPy[YF{\SCrbjDBdI9DNWO{ZYPj[Y51ew>? NGL5TmozPDFyMEG0NC=>
Huh7 M2W5SGZ2dmO2aX;uJGF{e2G7 NUDn[ms5PeLCk{GwxsBv\y:vbB?= NFfqW20yOiCq Mn\6bY5kemWjc3XzJGFxd0JvY4Lld4NmdnS|IIfpeIhwfXRiaX7obYJqfGmwZzDz[YNz\XSrb36= M{[2NlI1OTByMUSw
BAECs NXLxWYVUTnWwY4Tpc44hSXO|YYm= NITmVYc2KM7:Zz;tcC=> Mn2zNE01KGh? NH:3UFJqdmS3Y3XzJJRp\SC{YYDp[EBl\XCqb4PwbI9zgWyjdHnvckBw\iCnTl;TJIF1KFOnckGxO|k> NUfCUItROjRyOEWyNlU>
Macrophages NWnubVJDTnWwY4Tpc44hSXO|YYm= Mmf1O|EhyrWP MVO2JIg> MWLpcohq[mm2czDseY5ie2mwIHnueIVzdmGuaYrheIlwdsLi M2\uNFI1ODN7N{Sw
Colo 205 Mmj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXThXmZQOC13IN88[{9uVA>? MnnGOFghcA>? MlO4bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5ic4XzdIVve2mxbjDjeYx1fXKnczD3bZRpKGGwIHXzeIlu[XSnZDDJR|UxKG:oII6xOUBv\y:vTB?= M3TxR|I{QTd|OUm2
Colo 205 MlTWSpVv[3Srb36gRZN{[Xl? MlXKNE4xOTJvMD6wNlUh|rypL33M MmrnNVQh\A>? M335ZZJm\HWlZYOgeIhmKGOub37v[4VvcWOrdImgc4YhS2:ubzCyNFUhS1OFcx?= Ml73NlM6PzN7OU[=
Colo 205 MY\BdI9xfG:|aYOgRZN{[Xl? NXPXeYRROC5zIN88[{9uVA>? M1X2UFAuOjRiaB?= Mk\PbY5lfWOnczDhdI9xfG:|aYOgc4YhS2:ubzCyNFUh[2WubIOgbY4he3W|cHXud4lwdiCldXz0eZJmew>? NWHGO3ZwOjN7N{O5PVY>
Colo 205 M4f3RmZ2dmO2aX;uJGF{e2G7 MXmwMlAyPSEQvHevcWw> MVSyOEBp M1zWb4lv\HWlZYOgeIhmKGW6cILld5Nqd25ib3[gSXIhe3S{ZYPzMZJmdGG2ZXSg[4Vv\XN? MXuyN|k4Ozl7Nh?=
Colo 205 NUDoT3BXTnWwY4Tpc44hSXO|YYm= MVSwMlAyPSEQvHevcWw> NVHIfGhsOjRiaB?= MV7pcohq[mm2czD0bIUh[WO2aY\peJkhd2ZiTV3Qdy=> MoCyNlM6PzN7OU[=
IBRS2 NH20VlFHfW6ldHnvckBCe3OjeR?= MljkOUDPxGdxbXy= M4DmZlAvPSCq M3PzW2ROW09? MoXr[Il{enWydIOgeIhmKEWUR1nDJIFv\CCJb3znbeKh M3PwWlI{QTZ|NUO0
IBRS2 NIDhRpZHfW6ldHnvckBCe3OjeR?= M{j5N|Uh|rypL33s MmrzNE42KGh? MYXEUXNQ MYflcohidmOnczDGUWRXKGmwZnXjeIlwdg>? MVSyN|k3OzV|NB?=
HeLa MWfGeY5kfGmxbjDBd5NigQ>? MV2yJO69VQ>? NUfSeoJ7OiCqwrC= Mn7NZZR1\W63YYTld{B1cGViVF7GMYlv\HWlZXSgd4VkemW2aX;uJI9nKEmOLUG1 M{nFO|I{QTVyOEmy
HFS  MVTGeY5kfGmxbjDBd5NigQ>? NGi1VVQxNTFizsznM41t M1S0UlI1KGh? MUXHUHRRKGW6cILld5Nqd25icnXhZ4hmeyCjIIDsZZRm[XViYYSgZ49v[2WwdILheIlwdnNiYYOgcI94KGG|IECuNFEhyrWpL33s MoLxNlM5QTR4M{O=
HFS  NIfxR2VHfW6ldHnvckBCe3OjeR?= NFTYR5YxNjBzINM1[{9udA>? M2LWTVI1KGh? MoHqbY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJIdtgWOxc4DobY5od2yrcHnkJJN6dnSqYYPlJIdmdmW|IHH0JFYhcA>? Ml3YNlM5QTR4M{O=
OVCAR-3 MlvvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIe4cYIy6oDVMUZCpO69VcLi NWLLXZhsOjUEoHi= M33SW4lv\HWlZYOgZUBtd3O|IH;mJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHoEoB?= MVyyN|gzPjl4NB?=
OVCAR-3 MVfGeY5kfGmxbjDBd5NigQ>? M1TNe|HjiJNzNdMg{txOyqB? NFP6UVAzPMLiaB?= MYrpcoR2[2W|IH71Z4xm[XJiZHHtZYdm NYXYPJBWOjN6Mk[5OlQ>
OVCAR-3 M3HDVmFxd3C2b4Ppd{BCe3OjeR?= NVvIWYt{OS1zMNMg{txO M3TT[|QhcA>? Mn:4bY5lfWOnczD0bIUh[WO2aY\heIlwdiCxZjDhdI9xfG:|aYOtdoVt[XSnZDDwdo91\Wmwcx?= Mn\oNlM5OjZ7NkS=
OVCAR-3 NVfsNnlSSXCxcITvd4l{KEG|c3H5 NWrrTIxrOTEEoN88US=> NVzmZmVJOjUEoHi= MW\pcoR2[2W|IHHjeIl3[XSrb36gc4Yh[2G|cHHz[ZM> MVWyN|gzPjl4NB?=
OVCAR-3 NXfy[I9TTnWwY4Tpc44hSXO|YYm= M3zpNVHjiJNzMNMg{txO M{G1N|I1yqCq MmfybY5lfWOnczDkbZNzfXC2aX;uJI9nKHSqZTDtbZRw[2ixbnTybYFtKHS{YX7zcYVu[nKjbnWgdI91\W62aXHs M4Lk[lI{QDJ4OU[0
OVCAR-3 MnLwSpVv[3Srb36gRZN{[Xl? M2HkPVHjiJNzMNMg{txO M{\LdVI1yqCq NYXIV|lvcW6mdXPld{Bnd3KvYYTpc44hd2ZicnXhZ5RqfmVib4j5[4VvKHOyZXPp[ZM> M4HsV|I{QDJ4OU[0
OVCAR-3 MVzGeY5kfGmxbjDBd5NigQ>? M1r3SFHjiJNzMNMg{txO NYTxRXRoOjUEoHi= MXLpcohq[mm2czDj[YxtKGGmaHXzbY9vKGGwZDDtbYdz[XSrb36= MUOyN|gzPjl4NB?=
MKN45 NUTvUI9wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\DO2lEPTB:MD6wNFEh|rypL33s MlPPNlM4QTN|NEK=
LOVO MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fLSWlEPTB;MD6xNkDPxGdxbXy= MlvoNlM4QTN|NEK=
A549 MljMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\Fc2lEPTB;MD6wOEDPxGdxbXy= MXuyN|c6OzN2Mh?=
MDA-MB-435 NIXFdZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7OdlhKSzVyPECuNFAyKM7:Zz;tcC=> M1u3VVI{Pzl|M{Sy
HepG2 M4HEPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRDBwMECxJO69\y:vbB?= MXWyN|c6OzN2Mh?=
HL-60 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTBTWM2ODxyLkCwNUDPxGdxbXy= M1vZSlI{Pzl|M{Sy

... Click to View More Cell Line Experimental Data

Protocol

Cell Research:

[5]

+ Expand
  • Cell lines: Human follicular lymphoma cell lines HF1A3, HF4.9 and HF28RA
  • Concentrations: 0 ng/mL -75 ng/mL
  • Incubation Time: 5 days
  • Method:

    HF1A3, HF4.9 cell viability upon the treatments is tested using double staining of cells with YO-PRO 1/PI and SYTO16/PI probes. To access cell proliferation, cells are treated with 0–100 ng/mL Brefeldin A in complete medium for 20 hours before adding 1 μCi/mL [methyl-3H]-thymidine for additional 4 hours at 37 °C. The incorporated radioactive thymidine is quantified by scintillation counting with Microbeta counter. To examine long-term effects of Brefeldin A treatment, cells are seeded at initial concentration 105 cells/mL and treated with 0-75 ng/mL Brefeldin A for up to 5 days. At the time indicated, a sample of cells is removed and viable cell number is assessed by standard Trypan Blue exclusion assay.


    (Only for Reference)

Solubility (25°C)

In vitro DMSO 4 mg/mL (14.26 mM)
Water Insoluble
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 280.36
Formula

C16H24O4

CAS No. 20350-15-6
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

ATPase Signaling Pathway Map

Related ATPase Products

Tags: buy Brefeldin A | Brefeldin A supplier | purchase Brefeldin A | Brefeldin A cost | Brefeldin A manufacturer | order Brefeldin A | Brefeldin A distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID